Alumis (ALMS) Operating Expenses (2023 - 2026)
Alumis' (ALMS) quarterly Operating Expenses came in at $150.5 million in Q2 2026, up 5.11% year-over-year from $143.2 million in Q2 2025, and up 53.0% quarter-over-quarter from $98.4 million in Q4 2025.
Analysis
Alumis (ALMS) Operating Expenses (2023 - 2026) Analysis & Trends
Alumis (ALMS) has reported Operating Expenses for 4 consecutive years, with $150.5 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Operating Expenses rose 5.11% year-over-year to $150.5 million in Q2 2026; TTM through Jun 2026 was $509.5 million, a 10.96% increase from a year earlier, with the FY2025 full-year figure at $477.9 million, up 58.89% from the prior year.
- Operating Expenses was $150.5 million for Q2 2026 at Alumis, up from $98.4 million in the prior quarter.
- Over five years, Operating Expenses peaked at $150.5 million in Q2 2026 and troughed at $37.6 million in Q2 2023.
- A 4-year average of $87.6 million and a median of $98.4 million in 2024 frame the typical range for Operating Expenses.
- The widest YoY moves for Operating Expenses: up 155.09% in 2025, down 0.25% in 2025.
- Over 4 years, Operating Expenses stood at $40.1 million in 2023, then surged by 145.74% to $98.6 million in 2024, then declined by 0.25% to $98.4 million in 2025, then surged by 53.0% to $150.5 million in 2026.
- The last three Operating Expenses figures came in at $150.5 million (Q2 2026), $98.4 million (Q4 2025), and $117.4 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 6.54 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 18.20 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 2.09 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 3.00 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -1.05 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 960.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1.06 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 2.60 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 367.83 Mn |
| 10 | Alumis | 1.27 Bn | 765.76 Mn | - | 150.52 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 150.52 Mn |
| Dec 31, 2025 | 98.37 Mn |
| Sep 30, 2025 | 117.36 Mn |
| Jun 30, 2025 | 143.21 Mn |
| Mar 31, 2025 | 118.92 Mn |
| Dec 31, 2024 | 98.62 Mn |
| Sep 30, 2024 | 98.40 Mn |
| Jun 30, 2024 | 56.14 Mn |
| Mar 31, 2024 | 47.59 Mn |
| Dec 31, 2023 | 40.13 Mn |
| Sep 30, 2023 | 43.76 Mn |
| Jun 30, 2023 | 37.62 Mn |